TriangleTrimodal therapy (TMT) within 45… (NCT06417190)
Trimodal therapy (TMT) within 45 days of neoadjuvant chemotherapy (NAC) trial for Muscle-Invasive Bladder Carcinoma (NCT06417190). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with muscle-invasive bladder cancer containing variant histology, stage T2–T4 without nodal or distant spread. Previous systemic treatment for this cancer or pelvic radiation excludes participation.
The idea: at least three chemotherapy cycles, with optional immunotherapy, precede bladder-preserving treatment. Bladder tumor removal precedes concurrent chemotherapy and radiation over four or six weeks. Researchers test whether this can start within forty-five days after initial chemotherapy, comparing outcomes with historical patients.
This phase 2 study plans 20 patients. Leslie Ballas leads at Cedars-Sinai in Los Angeles, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.